Thus, our previously reported 3p14.1-p13 deletions in AML 2 and the newly identified aberrations in prostate cancer 1 represent distinct tumor subgroups that seem to share a common underlying tumor biology. However, most likely additional aberrations are necessary for tumor development. In prostate cancer with the fusion gene TMPRSS2-ERG one event has already been identified, and in AML in line with a potential multistep pathogenesis, all 3p deleted cases had an underlying NPM1 mutation in the presence of an internal tandem duplication of the FLT3 tyrosine kinase gene (FLT3-ITD).
Lenalidomide is an immunomodulatory drug related to thalidomide that has recently been reported to have significant single-agent activity in relapsed chronic lymphocytic leukemia (CLL), with response rates of 35-50% including some complete responses. 1, 2 The mechanism of action is unknown, but appears to be immune-mediated given that lenalidomide alters cytokine levels and stimulates T-and natural killer-cell function and lacks cytotoxicity against CLL in vitro.
3 In CLL patients, the administration of lenalidomide can be associated with tumor flare, a syndrome of painful enlarging lymphadenopathy, increased white count, fever and rash. 1, 2 This tumor flare can potentially escalate to become life-threatening, with renal insufficiency, tumor lysis or a systemic inflammatory response. 4, 5 The mechanism of tumor flare remains unknown.
Given the high reported response rates with lenalidomide and its theoretical potential to help preserve immune function, we undertook this phase I study of lenalidomide in combination with fludarabine rituximab to determine the maximum tolerated dose of lenalidomide in combination with fludarabine rituximab, as well as to assess any preliminary signs of efficacy. This prospective study enrolled patients with previously untreated CLL/small lymphocytic lymphoma who required therapy based on the 1996 NCI WG criteria. Adequate organ function was required and was defined as ANC 41000/ml, platelets 450 000/ml, creatinine p1.5 mg/dl and total bilirubin p1.5 mg/dl. All patients tested negative for hepatitis B and C, and none had autoimmune hemolytic anemia. The study was approved by the Dana-Farber Harvard Cancer Center Institutional Review Board, and all patients signed informed consent before the initiation of the therapy.
In total, six cycles of combination therapy followed by two cycles of consolidation lenalidomide were originally planned. Fludarabine was given at the standard dose of 25 mg/m 2 intravenously (i.v.) for 3-5 days depending on the dose level, with rituximab 375 mg/m 2 on day 1 of each 28-day cycle. In order to minimize the infusion reactions in the first cycle, all patients received a split dose of rituximab, with 50 mg/m 2 on day 1 followed by 325 mg/m 2 on day 3. The lenalidomide dosing began at 2.5 mg daily for days 1-21 of a 28-day cycle. The plan was to start at dose level 1, with 3 days of fludarabine and 2.5 mg lenalidomide per day, with the lenalidomide dose levels subsequently being increased to 5 mg and then 10 mg, followed by the addition of fludarabine on days 4-5 and ultimately by escalation of the lenalidomide from 10 to 25 mg in 5-mg increments. De-escalation from dose level 1 decreased the lenalidomide dose to 2.5 mg every other day in dose level-1 and then decreased the fludarabine dose to 2 days in dose level-2. All patients received infectious prophylaxis with trimethoprimsulfamethoxazole and acyclovir (or equivalent). For prevention of deep venous thrombosis, aspirin 81 mg daily was given to patients with platelet counts over 50 000/ml. During the first cycle of therapy, all patients received allopurinol and i.v. hydration with therapy; chemistries including a full comprehensive panel, calcium, phosphate, uric acid and lactate dehydrogenase were checked 2-3 times per week and additional i.v. hydration provided at that time if needed. Tumor flare was treated with ibuprofen, oxycodone and/or glucocorticoids (a Medrol pak).
The study used a standard 3 þ 3 dose escalation design, with dose limiting toxicity (DLT) assessed in the first 28-day cycle only. DLT was defined as grade 3 or greater non-hematological toxicity (except grade 4 for allergic reactions), grade 4 neutropenia or thrombocytopenia, grade 3 febrile neutropenia, or a 42-week treatment delay in initiation of cycle 2. Hematological toxicity was assessed according to the NCI-WG 1996 criteria, while non-hematological toxicity was assessed according to the Common Terminology Criteria for Adverse Events v3.0.
Nine patients were enrolled on this study, as detailed in Table 1 . The median age was 59 years, with a median time from
Letters to the Editor diagnosis of 66.1 mos (12-83 mos). Two-thirds had advanced Rai-stage disease and a majority had unmutated IgVH and were positive for zeta-chain-associated protein kinase 70.
Of four patients enrolled at the starting dose level, two experienced dose-limiting toxicities. The course of each patient on study is presented in Table 1 . The second patient developed tumor flare concomitant with prolonged neutropenia, which persisted until day 50 of cycle 1, despite the discontinuation of lenalidomide on day 8 and the use of myeloid growth factors. Because of this DLT, the cohort was expanded to enroll up to six patients, but the third patient on study developed a DLT also a syndrome of rash, fever, myalgias and rhabdomyolysis (grade 4 creatine kinase) on day 19 of cycle 1. Lenalidomide and simvastatin were discontinued, and the patient tested positive for influenza. Given the influenza and longstanding simvastatin, which may have pre-disposed to rhabdomyolysis, this patient was re-challenged with study therapy following recovery from influenza and while remaining off simvastatin, but developed a very similar syndrome of rash, fever and rhabdomyolysis after only day 1 of study therapy in cycle 2. He was, therefore, removed from study for this syndrome, which was clearly related to study therapy. Patient 4 was diagnosed with a secondary malignancy when a pre-existing region of lymphadenopathy progressed on therapy, making this event unlikely related to the study therapy.
Given these two DLTs in four patients, the study proceeded to enroll five patients to dose level-1, which included 3 days of fludarabine, rituximab as described above and lenalidomide 2.5 mg every other day for the first 21 days of a 28-day cycle. Five patients were enrolled on this cohort. Two were able to complete six cycles of study therapy, one of whom went on to two cycles of consolidation. The other three, however, had significant toxicities, including grade 3-4 cytopenias, grade 3 rash and hand-foot syndrome. Patient 6 did not have adequate platelet recovery to receive cycle 4, despite initial normalization of his platelet count and disease response. Patient 8 had grade 4 neutropenia and thrombocytopenia, causing the lenalidomide to be held every cycle after just a few doses and mandating per protocol dose reductions to 2 days of fludarabine. Despite myeloid growth factors, this patient still had grade 3-4 cytopenias, which mandated dose reductions that caused her to come off the study. Patient 9 had recurrent grade 3 rash, grade 3 tumor flare and hand-foot syndrome, as well as neutropenia, in each of the first three cycles. Lenalidomide was again held in each cycle and steroids were given, which did resolve the tumor flare in a given cycle, although it recurred in each subsequent cycle. Dose reduction to 2 days of fludarabine was again required, but due to her recurrent tumor flare symptoms this patient withdrew from the study. A summary of treatment delays, dose reductions and toxicities is shown in Table 2 .
The response rate on an intent-to-treat basis was 56% (90% CI, 25-83%). One patient had a complete remission, one a nodular partial remission, three partial remission and one stable disease. Three patients were not evaluable, owing to early withdrawal from the study in two cases and a second malignancy in one case. Given the toxicity of the therapy, this level of activity did not justify continuing the study, which was therefore closed to enrollment. Although correlative studies to assess immune cell subsets, CD20 expression and cytokine production were planned and completed on a subset of these patients, the results were difficult to interpret owing to the frequent interruption of study therapy and the short duration of time most patients remained on study.
Here we report the results of the first study to combine chemoimmunotherapy with lenalidomide, an immunomodulatory Letters to the Editor derivative of thalidomide, which has been previously shown to have clinical activity in relapsed CLL. 1, 2 The mechanism of action of the lenalidomide is unknown, but it is not cytotoxic to CLL cells in vitro. Instead, lenalidomide has been found to upregulate CD154 as well as CD80, 86 and 95 on the surface of CLL cells 3, 6 and to induce T-cell activation in patients with CLL.
3 These activities can potentially restore the T-cell defect in CLL and increase antibody production. 6 Our hypothesis in undertaking this study was that administering lenalidomide concurrently with fludarabine-rituximab chemoimmunotherapy might result in relative preservation of immune function and enhance activity without toxicity, given their distinct mechanisms of action.
Unfortunately, what was found was that even at very low doses of fludarabine and lenalidomide, with rituximab given in split doses initially, this combination was very poorly tolerated when administered concurrently, at least to those patients with a large disease burden. The patient population treated in this study was a difficult one, with two-thirds having advanced-stage disease, several with bulky nodal disease and most with adverse prognostic markers. Clinically, the co-administration of chemoimmunotherapy, with potential for rapid cytoreduction and myelosuppression, with lenalidomide, with induction of tumor flare reaction and likely activation of the CLL cells themselves, followed also by myelosuppression, proved unstable. Several patients developed serious idiosyncratic reactions, including a febrile syndrome with rash and rhabdomyolysis, and a febrile syndrome with severe nodal pain, rash and hand-foot syndrome, both of which resulted in those patients coming off study. The nature and timing of these reactions were not predictable, and if the patient was re-challenged with the study drugs the reactions recurred. Other patients developed what appeared to be synergistic myelosuppression, with grade 3-4 neutropenia and thrombocytopenia persisting for a week or more despite 3 days of fludarabine rather than 5 days, lenalidomide 2.5 mg every other day and myeloid growth factors. These unpredictable reactions and unexpectedly persistent myelosuppression made it difficult to deliver adequate amounts of either fludarabine or lenalidomide, which further resulted in lackluster disease response. Taken together, these factors led us to close the study early.
This experience is not dissimilar from previously described severe tumor flare reactions that occurred with single agent lenalidomide at higher doses or in the setting of renal insufficiency.
4,5 The high tumor burden of our patients may have promoted significant reactions even with low doses of lenalidomide, such that reduction of tumor burden with chemotherapy before the initiation of lenalidomide therapy might decrease these reactions. An ongoing related study introduces lenalidomide on day 7, and although significant toxicities of neutropenia, skin rash, infection and thrombosis have been observed, tumor flare has been minimal and some patients have tolerated dose escalation.
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In summary, this study found that the concurrent administration of FR with lenalidomide was not tolerable, owing to idiosyncratic drug reactions, tumor flare and myelosuppression. Other ongoing studies are assessing the use of lenalidomide for consolidation after a complete course of chemo-immunotherapy, or sequential administration of lenalidomide after chemo-immunotherapy during each 1-month cycle. Elucidation of the mechanism of action of lenalidomide in CLL will aid in the design of rational combination therapies; for example, if a relatively intact immune system proves to be required for the effectiveness of lenalidomide in CLL, its use after fludarabinebased chemo-immunotherapy may not be as optimal as combinations with immunotherapies or non-myelosuppressive targeted therapies. Consistent with this hypothesis is the report of Ferrajoli et al.,
8 who combined rituximab with lenalidomide and found improved activity with decreased toxicity compared with lenalidomide alone. The results of this and other ongoing studies will help to clarify the optimal role of lenalidomide in the therapy of CLL.
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Median number of cycles 3 (1-6) Delay of next cycle 5/9 pts Lenalidomide held in mid-cycle at least once 6/9 pts Dose reduction 4/9 pts
Major toxicities (grade 3-4) Neutropenia 6/9 (67%) Thrombocytopenia 2/9 (22%) Tumor flare 2/9 Rash 2/9 Hand-foot syndrome 1/9 Creatine kinase 1/9 ALT/AST 1/9 Uric acid 1/9
Response rate 5/9 (56%) (90% CI, 25-83%) Abbreviations: ALT, alanine transaminase; AST, aspartate aminotransferase; CI, confidence interval; pts, patients. Acute myeloid leukemia (AML) is heterogeneous in clinical features and molecular pathogenesis. Cooperating alterations of several genes, including oncogenes or tumor suppressor genes, lead to AML development. 1 AML leukemogenesis is thought to require at least two different types of genetic change: class I mutations, which confer a proliferative or survival advantage; and class II mutations, which block myeloid differentiation and provide self-renewability. 1 In hematological malignancies with 11p15 translocations, the nucleoporin (NUP) 98 gene is reportedly fused to various partner genes, often including homeobox genes, such as HOXA9, A11, A13, C11, C13, D11, D13 and PMX1.
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2 With respect to the oncogenic mechanism of NUP98-HOX fusion proteins, a previous study using a murine bone marrow transplantation assay revealed that NUP98-HOXA9, -HOXD13 and -PMX1 fusion proteins induce myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN), which progress to AML.
2 This latency period indicates that additional genetic events might be required for leukemic transformation. Therefore, we examined somatic mutations of the FLT3, KIT, WT1, RUNX1, CEBPA, NPM1, NRAS, KRAS and MLL genes, which are prevalent in AML, in leukemia patients with NUP98 fusion genes. This study was approved by local ethical committee.
Sixteen patients with chromosomal 11p15 translocations included nine with NUP98-HOXA9, two with NUP98-HOXA13, two with NUP98-HOXA11 and one each with NUP98-HOXC11, NUP98-HOXD11, NUP98-HOXD13 or NUP98-NSD3 (Table 1 ). The partner gene fused to NUP98 could not be detected in one patient with t(4;11)(q21;p15); however, fluorescent in situ hybridization analysis using a probe containing NUP98 showed split signals (data not shown). No patients had any additional chromosomal abnormality except for chromosomal 11p15 translocations (Supplementary data). Two patients with t(7;11)(p15;p15) had double NUP98 fusion transcripts: patient (PN) 13 had simultaneous NUP98-HOXA9 and NUP98-HOXA13 fusions, and PN14 had simultaneous NUP98-HOXA9 and NUP98-HOXA11 fusions. In all, 15 of the 16 patients with NUP98-related hematological malignancies were diagnosed as having myeloid malignancies, and the other patient (PN16) were initially diagnosed as having T-cell nonHodgkin's lymphoma with t(4;11)(q21;p15), and transformed into acute myelomonocytic leukemia with the same t(4;11) (lineage switch). Patients with myeloid malignancies consisted of 10 patients with AML, 2 patients with MDS and 3 patients with MPN.
We examined the internal tandem duplications (ITDs) and tyrosine kinase domain (TKD) mutations of the FLT3 gene in 16 patients, and detected ITDs in nine (56.3%) patients, and TKD mutations in none (Table 1, Figure 1a) . The incidence of FLT3-ITD in our study was much higher than that in an AML cohort reported previously (12-35%).
1 A high frequency of FLT3-ITD was previously reported in 30-35% of AML patients with either normal karyotype or with t(15;17)(q21;q11) resulting in PML-RARA, and in 70% of AML patients with t(6;9)(p23;q34) resulting in DEK-CAN/NUP214.
1 Interestingly, both NUP98 and NUP214 encode a part of the nucleoporin complex. The general activation effects on reporters of the DEK-CAN/NUP214 fusion protein are specific for myeloid cells. 3 Moreover, in murine bone marrow transplantation assays, NUP98-related fusion proteins such as NUP98-HOXA9, -HOXD13 and -PMX1 induced MDS or MPN, which progressed to AML. 2 These results demonstrate that the nucleoporin-related proteins share a common ability for myeloid differentiation. Furthermore, the very tight correlation between nucleoporin-related fusion genes and FLT3-ITD suggest that FLT3-ITD may contribute to the myeloid leukemogenesis involved in nucleoporin-related fusions.
We further examined mutations of the KIT, WT1, AML1, CEBPA, NPM1, NRAS, KRAS and MLL genes, 4 which are prevalent in AML. KIT, NRAS and KRAS mutations were found in four (25.0%), three (18.8%) and two (12.5%) patients, respectively (Table 1, Figure 1b) . WT1 aberrations were found in eight patients (50.0%; Table 1, Figure 1c) . No mutations were found in the other four genes (RUNX1, CEBPA, NPM1 and MLL). The mutations in KIT were all missense mutations including Val399Ile, Met541Leu and Asp816Val, and all mutations of NRAS and KRAS were Gly13Asp. All of KIT, NRAS and KRAS mutations were heterozygous. The aberrations in WT1 comprised a frameshift insertion of exon 7 in four patients, missense mutation of exon 9 in one, deletion of exon 5 in one and deletion of the whole cording region in two. Frameshift and
